Cassava Sciences, Inc. (NASDAQ:SAVA) to Post FY2025 Earnings of ($1.75) Per Share, HC Wainwright Forecasts

Cassava Sciences, Inc. (NASDAQ:SAVA) – Equities researchers at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Cassava Sciences in a research report issued on Tuesday, October 8th. HC Wainwright analyst V. Bernardino expects that the company will post earnings of ($1.75) per share for the year. HC Wainwright has a “Buy” rating and a $116.00 price target on the stock. The consensus estimate for Cassava Sciences’ current full-year earnings is ($5.70) per share.

Cassava Sciences (NASDAQ:SAVA) last posted its earnings results on Thursday, August 8th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.44) by $0.57. During the same period in the previous year, the firm earned ($0.63) EPS.

Separately, Rodman & Renshaw reaffirmed a “buy” rating and set a $107.00 price target on shares of Cassava Sciences in a research note on Thursday, August 8th.

Cassava Sciences Stock Up 3.8 %

Cassava Sciences stock opened at $25.80 on Thursday. Cassava Sciences has a 52 week low of $8.79 and a 52 week high of $42.20. The business has a 50-day simple moving average of $28.22 and a 200 day simple moving average of $22.17. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -18.13 and a beta of -0.63.

Institutional Investors Weigh In On Cassava Sciences

Hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its stake in shares of Cassava Sciences by 4.2% in the 2nd quarter. Arizona State Retirement System now owns 11,495 shares of the company’s stock valued at $142,000 after acquiring an additional 468 shares during the last quarter. Janney Montgomery Scott LLC raised its position in Cassava Sciences by 3.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 14,690 shares of the company’s stock valued at $298,000 after purchasing an additional 506 shares during the last quarter. Profund Advisors LLC raised its position in Cassava Sciences by 4.6% during the 2nd quarter. Profund Advisors LLC now owns 13,440 shares of the company’s stock valued at $166,000 after purchasing an additional 591 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in Cassava Sciences by 5.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 12,149 shares of the company’s stock valued at $247,000 after purchasing an additional 650 shares during the last quarter. Finally, NBC Securities Inc. raised its position in Cassava Sciences by 9.3% during the 1st quarter. NBC Securities Inc. now owns 7,650 shares of the company’s stock valued at $155,000 after purchasing an additional 650 shares during the last quarter. Institutional investors own 38.05% of the company’s stock.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.